Comparison of VATS Segmentectomy and Lobectomy for pT1c pN0 NSCLC

We conducted a retrospective multicentre observational study reviewing all consecutive patients with pT1c pN0 NSCLC who underwent a planned complete (R0) VATS segmentectomy (VS) or VATS lobectomy (VL) with lymphadenectomy between January 2014 and October 2021. Patients were treated by 1 of the 5 board-certified thoracic surgeons in 4 different centres across Switzerland. All surgeons had a large experience in VATS anatomical resections. The study population included patients aged over 18 years who underwent VS or VL with mediastinal lymphadenectomy for pT1c pN0 NSCLC (adenocarcinoma, squamous cell carcinoma, large cell carcinoma) only. Eligible patients had to have no history of ipsilateral thoracotomy, no previous chemotherapy or radiotherapy. All patients received contrast-enhanced thoracic CT and a fluorodeoxyglucose-positron emission tomography CT within 30 days prior to the surgery. All tumours had a consolidation-to-tumour ratio of 0.5 or more. Exclusion criteria encompassed all other types of anatomical or extra-anatomical lung resections (wedge, bilobectomy, sleeve lobectomy, pneumonectomy), middle lobectomy, open procedures, synchronous tumour, histology different than previously cited (carcinoid tumour, small-cell lung carcinoma, minimally invasive adenocarcinoma), an 8th edition TNM stage different than pT1c pN0 R0, pleural invasion, multiple lesions, nodal involvement or incomplete resections. Two groups were defined according to the extension of the resection: VL or VS.

Free full text: Click here

Forster C., Abdelnour-Berchtold E., Bédat B., Perentes J.Y., Zellweger M., Sauvain M.O., Christodoulou M., Triponez F., Karenovics W., Krueger T, & Gonzalez M. (2023). Local control and short-term outcomes after video-assisted thoracoscopic surgery segmentectomy versus lobectomy for pT1c pN0 non-small-cell lung cancer. Interdisciplinary Cardiovascular and Thoracic Surgery, 36(2), ivad037.

Publication 2023

Adenocarcinoma Carcinoid tumour Chemotherapy Fluorodeoxyglucose Large cell carcinoma Lung Lymphadenectomy Mediastinal Nsclc Patients Pleural Pneumonectomy Positron emission tomography Radiotherapy Segmentectomy Small cell lung carcinoma Squamous cell carcinoma Surgeons Surgery Synchronous tumour Thoracotomy Tumour Vats

Corresponding Organization : University of Lausanne

Other organizations : University of Geneva, Hospital Neuchâtel

Top 5 similar protocols

Variable analysis

independent variables

Surgical procedure (VATS segmentectomy or VATS lobectomy)

dependent variables

Outcomes of the surgical procedures

control variables

Patients with pT1c pN0 NSCLC (adenocarcinoma, squamous cell carcinoma, large cell carcinoma)
Patients aged over 18 years
Patients with no history of ipsilateral thoracotomy
Patients with no previous chemotherapy or radiotherapy
Patients with contrast-enhanced thoracic CT and fluorodeoxyglucose-positron emission tomography CT within 30 days prior to the surgery
Patients with a consolidation-to-tumour ratio of 0.5 or more
Exclusion of other types of anatomical or extra-anatomical lung resections, middle lobectomy, open procedures, synchronous tumour, histology different than cited, 8th edition TNM stage different than pT1c pN0 R0, pleural invasion, multiple lesions, nodal involvement or incomplete resections

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!